Multidose Safety and Tolerability Study of (Arikace™) for Inhalation In Cystic Fibrosis Patients

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Insmed
ClinicalTrials.gov Identifier:
NCT00558844
First received: November 13, 2007
Last updated: May 3, 2012
Last verified: May 2012

November 13, 2007
May 3, 2012
June 2007
June 2009   (final data collection date for primary outcome measure)
To evaluate the safety and tolerability of 28 days of daily dosing of nebulized Arikace™, liposomal amikacin for inhalation. [ Time Frame: 28 Days of daily dosing ] [ Designated as safety issue: Yes ]
To evaluate the safety and tolerability of 28 days of daily dosing of two dose cohorts of nebulized Arikace™, liposomal amikacin for inhalation. [ Time Frame: 28 Days of daily dosing ]
Complete list of historical versions of study NCT00558844 on ClinicalTrials.gov Archive Site
  • To access pharmacokinetics (PK) of Arikace™ in serum and urine, and evaluate sputum amikacin levels [ Time Frame: 28 Days of daily dosing ] [ Designated as safety issue: Yes ]
  • To evaluate change in Pulmonary function [ Time Frame: 28 Days of daily dosing ] [ Designated as safety issue: Yes ]
  • To evaluate change in density of Pseudomonas aeruginosa in sputum [ Time Frame: 28 Days of daily dosing ] [ Designated as safety issue: Yes ]
  • To evaluate time to and duration of systemic anti-Pseudomonal rescue therapy [ Time Frame: 28 Days of daily dosing ] [ Designated as safety issue: No ]
  • To evaluate change in CFQ-R measurements [ Time Frame: 28 Days of daily dosing ] [ Designated as safety issue: Yes ]
  • Exploratory evaluation of a Cystic Fibrosis Symptom Diary (CFSD) [ Time Frame: 28 Days of daily dosing ] [ Designated as safety issue: No ]
  • Exploratory evaluation of durability of clinical benefit [ Time Frame: 28 days of daily dosing ] [ Designated as safety issue: No ]
  • To access pharmacokinetics (PK) of Arikace™ in serum and urine, and evaluate sputum amikacin levels [ Time Frame: 28 Days of daily dosing ]
  • To evaluate change in Pulmonary function [ Time Frame: 28 Days of daily dosing ]
  • To evaluate change in density of Pseudomonas aeruginosa in sputum [ Time Frame: 28 Days of daily dosing ]
  • To evaluate time to and duration of systemic anti-Pseudomonal rescue therapy [ Time Frame: 28 Days of daily dosing ]
  • To evaluate change in CFQ-R measurements [ Time Frame: 28 Days of daily dosing ]
  • Exploratory evaluation of a Cystic Fibrosis Symptom Diary (CFSD) [ Time Frame: 28 Days of daily dosing ]
Not Provided
Not Provided
 
Multidose Safety and Tolerability Study of (Arikace™) for Inhalation In Cystic Fibrosis Patients
Phase 1b/2a Multidose Safety and Tolerability Study of Liposomal Amikacin for Inhalation (Arikace™) in Cystic Fibrosis Patient With Chronic Infections Due to Pseudomonas Aeruginosa.

This is a study to determine the safety and tolerability of 28 days of daily dosing of 560 mg of Arikace™ versus placebo in patients who have Cystic fibrosis.

Cystic fibrosis (CF) is a gentic disease resulting from mutations in a 230 kb gene on chromosome 7 known as the cystic fibrosis transmembrane conductance regulator (CFTR). Study subjects with CF manifest pathological changes in a variety or organs that express CFTR. The lungs are frequently affected, the sequelae being chronic infections and airway inflammation. The principal goal of both treatment of subjects with CF is to slow the chronic deterioration of lung function.

Study subjects will be randomized to receive either study drug or placebo (1.5% NaCl) by inhalation via a PARI eFlow nebulizer. Each subject will complete 28 days of daily dosing. All study patients will be followed for safety, pharmacokinetics, clinical and microbiologic activity for 56 days post completion of study treatment. The total study period will be up to 84 days, with screening visit occurring within the preceding 14 days prior to study day 1. Patients will be clinically evaluated during the first 48 hours post first study dose and weekly for the 28 day treatment period and during the follow up visits at study days 35, 42, 49, 56, 70 and 85 days to determine safety and tolerability, pharmacokinetics (PK) and clinical and microbiologic activity.

Clinical laboratory parameters, audiology testing, clinical adverse events and pulmonary function will be evaluated for all study subjects in order to determine the qualitative and quantitative safety and tolerability of Arikace™ compared to placebo. Serum, urine and sputum specimens will be collected at periodic intervals to assess PK. Additionally, sputum samples will be collected to determine changes in bacterial density. Pulmonary function testing and CFQ-R measurements will be assessed at selected time points throughout the study. An exploratory evaluation of a Cystic Fibrosis Symptom Diary (CFSD) will also be implemented.

Interventional
Phase 1
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Cystic Fibrosis
Drug: Arikace™
Subjects will be randomly assigned to study drug dose of of Arikace™ or placebo in accordance with a code provided by the Sponsor/CRO. Randomization will be made in a 2:1 allocation between Arikace™ and placebo. They will be blinded whether they receive Arikace™ or Placebo Study subjects will receive Arikace™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
  • Active Comparator: A
    Arikace at 560 mg
    Intervention: Drug: Arikace™
  • Placebo Comparator: B
    Matching placebo
    Intervention: Drug: Arikace™
Clancy JP, Dupont L, Konstan MW, Billings J, Fustik S, Goss CH, Lymp J, Minic P, Quittner AL, Rubenstein RC, Young KR, Saiman L, Burns JL, Govan JR, Ramsey B, Gupta R; Arikace Study Group. Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection. Thorax. 2013 Sep;68(9):818-25. doi: 10.1136/thoraxjnl-2012-202230. Epub 2013 Jun 8.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
46
June 2009
June 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female study subjects must be adults (≥ 6 years of age)
  • Confirmed diagnosis of CF
  • History of chronic infection with P.aeruginosa
  • FEV1 ≥40% of predicted at Screening
  • Ability to comply with study medication use, study visits and procedures
  • Ability to produce 0.5 grams of sputum

Exclusion Criteria:

  • Administration of any investigational drug within 8 weeks to Study Day 1
  • Emergency room visit or hospitalization for CF or respiratory-related illness within 4 weeks prior to screening
  • History of alcohol, medication or illicit drug abuse within 1 yr. to screening
  • History of lung transplantation
  • Female of childbearing potential who are not practicing an acceptable method of birth control or who are lactating
  • Positive Pregnancy test
  • Use of any anti-pseudomonal antibiotics within 28 days prior to Study Day 1
  • Initiation of chronic therapy within 28 days prior to Study Day 1
  • History of sputum or throat swab culture yielding Burkholderia cepacia within 2 years prior to screening
  • History of mycobacterial and/or Aspergillus infection requiring treatment within 2 years prior to screening
  • History of biliary cirrhosis with portal hypertension, or splenomegaly
Both
6 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00558844
TR02-106
Yes
Insmed
Insmed
Not Provided
Principal Investigator: J. P. Clancy, M.D. University of Alabama, 620 ACC, 1600 7th Avenue, South Birmingham, AL 35233
Insmed
May 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP